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1. Introduction
Modern medical genetics as a well-defined field of medicine has developed so 
fast since its origins half a century ago that we cannot bear in mind how long time 
ago its roots and beginnings came from.
It can be argued that genetics overall was based on measuring the problems 
of human hereditary features and inherited diseases, since before the twentieth-
century acceptance of Mendelian laws of heredity. Thus, medical genetics, viewed 
from its broadest perspective, is perhaps the oldest area of genetics and not a recent 
area that it is sometimes believed.
2. Modern genomics in medicine
During the years, with developments in cellular and molecular biology, the 
field of medical genetics expanded from a small clinical subspecialty focused at 
describing a few rare hereditary disorders to a recognized medical specialty whose 
principles and approaches are essential parts of the diagnosis and management of 
many disorders, both common and rare. These genetic concepts and approaches are 
not restricted to any one medical specialty or subspecialty, as they permeate many, 
and perhaps all areas of medicine.
The medical geneticist is usually a physician who works as part of a team of 
clinical providers, including many other physicians, nurses, and genetic counselors, 
to evaluate patients and their relatives for possible hereditary diseases. They char-
acterize the patient (or proband) through analyses of personal and family history 
and physical examination; assess risk and possible modes of inheritance; indicate 
diagnostic testing; manage prevention, treatment, and surveillance; and participate 
in communicating to other family members at risk for the disorder.
During the twentieth century, it gradually became clear that hereditary fac-
tors were implicated in many conditions and that different genetic mechanisms 
were involved. Virtually, any disease is the result of the interaction of genes and 
environment, but the relative influence of the genetic component may be large or 
small. Traditionally, genetic conditions have been classified into three categories: 
monogenic, chromosomal, and multifactorial disorders. However, it is becoming 
increasingly evident that the interplay of different genes (polygenic inheritance) 
is essential in disease and that an additional category—acquired somatic genetic 
disease—should also be included.
Improvements in all areas of medicine, mainly public health and therapeutics, 
resulted in modifying patterns of diseases, with improving recognition of the role 
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of genetic factors for most of common disorders or even for the susceptibility to 
infectious diseases. For complex chronic degenerative diseases of adult onset, their 
overall contribution of heritability has been identified, as life expectancy increases 
and high-throughput technologies improve. These provide the opportunity for 
understanding the interactions between the genetic and environmental factors of 
diseases such as cancer, Alzheimer’s disease, diabetes mellitus, macular degenera-
tion, and cardiomyopathy.
In recent years, we have been facing the applications of modern genomics to the 
practice of medicine. With robust molecular biology technologies, one can identify 
the actionable mutations present in a tumor and establish the profile of its pattern 
of RNA expression, which are currently being used for determining prognosis and 
choosing appropriate targeted therapies for individual cancer patients. Another 
application is how modern genomic approaches are increasing our abilities in risk 
assessment and helping provide more accurate genetic counseling to patients and 
families affected with hereditary diseases as well as advances in prenatal diagnosis.
There are further examples of applications of genomics to individualized health 
care: screening asymptomatic individuals for genetic predisposition to various diseases 
in order to improve health care, population-based newborn screening for preventable 
and treatable genetic diseases, identifying couples that are carriers for autosomal reces-
sive or X-linked diseases that could affect their children before conception, prenatal 
screening of the fetus for aneuploidy by maternal cell-free DNA, and applications of 
pharmacogenomics on the detection of individual variation affecting drug therapy, 
which can be used to improve therapeutic efficacy and reduce adverse events.
At the beginning of the twenty-first century, the Human Genome Project (HGP) 
provided a virtually complete sequence of human genome from which now derives the 
efforts to catalog all human genes, understand their structure and regulation, deter-
mine the extent of their variation in different populations, and uncover how genetic 
variation contributes to susceptibility. The whole genome of any individual can now be 
sequenced rather than sequencing one gene at a time. These achievements are making 
possible the practice of genomic medicine, which aims at applying a wide analysis of the 
human genome and its products, including the epigenetic regulation of gene expres-
sion, gene variation, and their interactions with the environment, to medical care.
The HGP has now been succeeded by the Human Variome Project, which seeks 
to compile and share the huge variation in human DNA sequence worldwide. This 
is potentially possible since whole exome sequencing (WES) and whole genome 
sequencing (WGS) have been increasingly performed in several population studies. 
For example, the 100,000 Genomes Project in the United Kingdom have recently 
achieved its goal of 100,000 genomes sequenced [1].
The study of genetics and its role in causing human disease is now widely 
acknowledged as being among the most exciting and influential areas of medical 
research. Certainly, their valuable discoveries have benefited patients and families 
dramatically, but this achievement will be measured by translating them into both 
treatment and prevention of disease.
3. Diagnostic advances
Advances over the past few years in mutation identification have provided 
many improvements in risk assessment, carrier detection, and prenatal diagno-
sis, allowing the detection of particular mutations with almost 100% accuracy. 
Laboratory testing for pathogenic (disease-causing) mutations is available for 
more than 4,500 genes associated to over 11,000 genetic conditions [2]. The 
better knowledge of the genes involved in hereditary disease and the rapidly 
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cheaper cost of DNA sequencing have permitted the identification of mutations in 
a patient or family member, and, therefore, the molecular diagnosis has become 
the standard of care for many conditions. DNA samples for testing are available 
not only from readily accessible tissues, such as a buccal scraping or blood sample, 
but also from tissues obtained by more invasive testing, such as chorionic villus 
sampling or amniocentesis.
For many hereditary disorders (including retinal degeneration, deafness, 
hereditary breast and ovarian cancer, Lynch syndrome, congenital myopathy, 
mitochondrial disorders, and hypertrophic or dilated cardiomyopathies), there is a 
substantial locus heterogeneity, that is, numerous genes are known to be mutated 
in different families with these disorders. When a patient with one of these highly 
heterogeneous disorders seeks for testing, recent advances in DNA sequencing make 
it possible to analyze large panels of dozens to more than 100 genes simultaneously 
and cost-effectively for mutations in every gene in which mutations have been seen 
previously to cause the disorder.
In those conditions for which even a large panel of relevant genes cannot be 
formulated for a particular phenotypically defined disorder, or for those geneti-
cally heterogeneous entities (e.g. intellectual disability, autism spectrum disorder) 
genetic diagnosis still can be achieved by analyzing all the coding exons of every 
gene (by WES) or by sequencing the entire genome (by WGS) to identify patho-
genic mutations.
The use of large gene panels and, even more so, WGS or WES raises special 
issues for sequence interpretation and risk assessment. As there are more genes 
being tested, the number of sequence differences between a patient’s DNA and that 
of an arbitrary reference sequence also increases; consequently, many previously 
undescribed variants will be found whose pathogenicity is unknown. These are 
so-called variants of uncertain significance (VUSs). This is the case, for example, of 
a missense mutation that results in the substitution of one amino acid for another in 
the encoded protein.
Thus, the interpretation of variants is a challenging and demanding area for all 
professional geneticists who provide molecular diagnosis. The American College of 
Medical Genetics and Genomics has recommended that variants be categorized into 
one of five classes: pathogenic, likely pathogenic, of uncertain significance, likely 
benign, and benign variants [3] Specialists in molecular diagnostics, human genom-
ics, and bioinformatics have developed a series of criteria for addressing the muta-
tion status. In most cases, none of these criteria is absolutely definitive but must 
be considered together to provide an overall assessment of the pathogenicity of a 
variant. Only those variants with a high probability of being pathogenic are com-
municated to the health professional and patient. It is arguable whether the testing 
laboratory should disclosure all VUSs, at the same time remaining available for 
updating as new information allow reclassification as either benign or pathogenic.
Despite all the time and effort put into interpretation, it is still impossible to 
ensure any clinical significance to the vast majority of all variants found through 
next-generation sequencing (NGS). There is a general concern that individuals and 
their clinical providers, when confronted with VUSs, will require additional unnec-
essary testing, with the potential for finding results with even more VUSs, thereby 
increasing patient’s uncertainty and anxiety. Moreover, there is the additional 
concern that even when a variant is known to be pathogenic and highly penetrant in 
families with multiple affected individuals, the true penetrance of a variant when it 
is found in individuals with a negative family history may be much lower.
Therefore, risk assessment and genetic counseling in this context are challenging 
processes and depend on continually addressing recently available information and 
communicating it properly to healthcare providers and patients.
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4. Ethical dilemmas
Each new advance in genetic technology has simultaneously brought new ethical 
concerns and raised new dilemmas about how science will be applied and utilized in 
medicine. At the center of this is the recognition that an individual’s genetic back-
ground is fundamental to both their identity and possible disease susceptibility. The 
most controversial field is prenatal genetics and reproductive choice, though national 
legal frameworks and cultural practices vary widely worldwide. The debate sur-
rounding the early ability to perform prenatal diagnosis for Down syndrome through 
invasive procedures in the mid-1960s is compared to the new technology that makes 
it possible to perform detailed genetic screening of the fetus on cell-free fetal DNA 
in the maternal blood or on embryos created through in vitro fertilization for preim-
plantation genetic diagnosis (PGD). Great controversy has taken place, and will go 
on, regarding the disclosure of unexpected but significant “incidental findings” from 
WES or WGS carried out for specific clinical purposes [4]. Furthermore today there is 
the technical feasibility of all newborns having their genome sequenced and screened 
for either childhood disorders or adult-onset conditions [5].
Advances in genetics attract great media attention, and this has brought the 
ethical debate to a wide public scenario. Issues about insurance, forensic science and 
DNA databases, patenting, gene therapy, population screening, cloning, stem cell 
research, and hybrids are considered to have major societal, commercial, and politi-
cal importance and therefore impact clinical and laboratory practice in medical 
genetics. On a global scale, it is essential to safeguard fundamental principles such 
as privacy, confidentiality, and respect for human life at all stages and ages.
Many of the questions raised do not have easy or definitive answers, which 
means that there will be a great need for both public awareness and properly trained 
clinicians and counselors to balance the needs of their patients and families with 
these ethical challenges for the foreseeable future.
5. Personalized and precision medicine
The aim of personalized or individualized medicine is to use knowledge of 
an individual’s genetic (or genomic) background relevant to the maintenance of 
health, prevention, and treatment of diseases as a routine part of medical care.
During the past 10 years, many examples of stratified medicine have blossomed, 
where the therapy of a particular disease is dependent on the germline or somatic 
variants patients may carry. These examples include monogenic rare diseases where a 
different treatment is recommended for patients with some types of germline muta-
tions in a specific gene, such as CFTR gene mutations that cause cystic fibrosis, and 
the molecular therapy targeted on an actionable somatic mutation of a specific tumor, 
such as the BRAF V600E mutation in malignant melanoma. The genetic (or genomic) 
diagnosis is therefore a crucial step toward the most appropriate treatment and/or 
prevention, what is so-called clinical utility or actionability [6, 7]. Recent initiatives 
are focusing on improving health outcomes through precision medicine especially in 
Oncology [8] (Table 1). This is a multidisciplinary integrated approach that analyzes 
human samples and personal data to improve health care through increased precision 
in the knowledge of mechanisms of both disease and drug response.
Personalized genomic medicine (PGM) is only one component of precision 
medicine, which means, in a broadest sense, it requires clinical care providers to 
combine genomic information with other types of information, such as biochemi-
cal or physiological testing results, neurodevelopmental history, environmental 
exposures, and psychosocial experiences. The most important goal is provide more 
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Tumor(s) Genes Clinical application(s)
Melanoma BRAF, CDKN2A, KIT Therapy; risk assessment; inherited 
susceptibility 
Breast and ovarian cancer BRCA1, BRCA2 Therapy; inherited susceptibility
Colorectal cancer MLH1, MSH2, MSH6, PMS2, 
EPCAM, BRAF, KRAS, NRAS
Therapy; inherited susceptibility
Non-small-cell lung cancer EGFR, BRAF, KRAS, ERBB2, RET, 
MET, ALK, ROS1
Therapy
Myelodisplastic syndrome TP53, GATA2, JAK2, ASXL1, ETV6, 
RUNX1, SF3B1, EZH2
Diagnosis; risk stratification
Acute myeloid leukemia KIT, CEBPA, FLT3, NPM1 Risk stratification
Table 1. 
Genetic/genomic profiling for selected malignancies (adapted from [8]).
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